Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2.

Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646–57. https://doi.org/10.1182/blood-2016-10-746933.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Rao H, Xu X, Li Z, Liao B, Wu H, et al. Clinical characteristics and outcomes of Castleman disease: a multicenter study of 185 Chinese patients. Cancer Sci. 2018;109(1):199–206. https://doi.org/10.1111/cas.13439.

Article  CAS  PubMed  Google Scholar 

Melikyan AL, Egorova EK, Kovrigina capital A CEMC, Subortseva IN, Gilyazitdinova EA, Karagyulyan SR, et al. Clinical and morphological features of different types of Castleman’s disease. Ter Arkh. 2015;87(7):64–71. https://doi.org/10.17116/terarkh201587764-71.

Seo S, Yoo C, Yoon DH, Kim S, Park JS, Park CS, et al. Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman’s disease: a single medical center experience. Blood Res. 2014;49(4):253–8. https://doi.org/10.5045/br.2014.49.4.253.

Article  PubMed  PubMed Central  Google Scholar 

van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–74. https://doi.org/10.1016/S1470-2045(14)70319-5.

Article  CAS  PubMed  Google Scholar 

Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32. https://doi.org/10.1182/blood-2004-12-4602.

Article  CAS  PubMed  Google Scholar 

van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24. https://doi.org/10.1182/blood-2018-07-862334.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6-directed therapy. Blood Adv. 2022;6(2):359–67. https://doi.org/10.1182/bloodadvances.2021004441.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851–9. https://doi.org/10.1182/blood.2019001160.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CS, Opat S, D’Sa S, Jurczak W, Lee HP, Cull G, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038–50. https://doi.org/10.1182/blood.2020006844.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhang MY, Cao XX, Zhou DB, Fajgenbaum DC, Dong YJ, et al. A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD. Leuk Lymphoma. 2022;63(3):618–26. https://doi.org/10.1080/10428194.2021.1999437.

Article  CAS  PubMed  Google Scholar 

Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J Immunol. 2019;202(10):2888–906. https://doi.org/10.4049/jimmunol.1800583.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. https://doi.org/10.1186/s12943-018-0779-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, et al. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton’s tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. Int J Cancer. 2018;142(1):202–13. https://doi.org/10.1002/ijc.31044.

Article  CAS  PubMed  Google Scholar 

Estupinan HY, Berglof A, Zain R, Smith CIE. Comparative analysis of BTK Inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021;9: 630942. https://doi.org/10.3389/fcell.2021.630942.

Article  PubMed  PubMed Central  Google Scholar 

Lang E, Sande B, Brodkin S, van Rhee F. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report. Ther Adv Hematol. 2022;13:20406207221082550. https://doi.org/10.1177/20406207221082552.

Article  PubMed  PubMed Central  Google Scholar 

Boriani G, Menna P, Morgagni R, Minotti G, Vitolo M. Ibrutinib and Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death. Chemotherapy. 2022. https://doi.org/10.1159/000528019.

Article  PubMed  Google Scholar 

Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111(1):155–8. https://doi.org/10.1007/s12185-019-02780-1.

Article  PubMed  Google Scholar 

Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–85. https://doi.org/10.1182/bloodadvances.2020004074.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bond DA, Woyach JA. Targeting BTK in CLL: beyond Ibrutinib. Curr Hematol Malig Rep. 2019;14(3):197–205. https://doi.org/10.1007/s11899-019-00512-0.

Article  PubMed  Google Scholar 

Dong Y, Zhang L, Nong L, Wang L, Liang Z, Zhou D, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Ann Hematol. 2018;97(9):1641–7. https://doi.org/10.1007/s00277-018-3347-0.

Article  CAS  PubMed  Google Scholar 

Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;129(10):4451–63. https://doi.org/10.1172/JCI126091.

Article  PubMed  PubMed Central  Google Scholar 

Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, et al. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021;5(17):3445–56. https://doi.org/10.1182/bloodadvances.2020004016.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019;133(16):1720–8. https://doi.org/10.1182/blood-2018-11-884577.

Article  CAS  PubMed  Google Scholar 

van Rhee F, Stone K. Storming the castle with TCP. Blood. 2019;133(16):1697–8. https://doi.org/10.1182/blood-2019-02-900803.

Article  CAS  PubMed  Google Scholar